Trial · NCT05535322
Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity
NCT05535322, Completed, Ana Palanca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity. Trials, record NCT05535322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05535322
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity
- NCT number
- NCT05535322
- Status
- Completed
- Enrollment
- 26,944 participants, actual
- Lead sponsor
- Ana Palanca
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- GLP-1RA, SGLT2i, Insulin, Miscellany
- First posted
- 2022-09-10
- Last updated
- 2022-09-28
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major acute cardiovascular events | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | In this work, this composite includes patients suffering from non-fatal acute myocardial infarction (AMI) and non-fatal stroke, transient ischemic attack (TIA), all-cause death, and, heart failure events occurring during the study period (from inclusion in the study until the event or the end of the study period, whichever came first). |
| Secondary | Major acute cardiovascular events without heart failure | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | In this work, this composite includes patients suffering from non-fatal acute myocardial infarction (AMI) and non-fatal stroke, transient ischemic attack (TIA) and all-cause death occurring during the study period (from inclusion in the study until the event or the end of the study period, whichever came first). |
| Secondary | AMI | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Acute myocardial infarction events occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Stroke | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Stroke events occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Heart Failure | Through study completion (from inclusion in the study until the event or the end of the study period, whichever came first) | Heart failure hospitalization occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | all-cause death | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Death from all causes occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Renal progression | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Sustained 40% reduction in eGFR occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | atrial fibrillation | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Events of atrial fibrillation episodes occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Hypoglycemia | From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Severe hypoglycemia requiring hospitalization occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first. |
| Secondary | Persistence | From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019. | Persistence on treatment was defined as the percentage of patients continuing treatment from the start of the study period or since the first prescription during the study period until evidence of discontinuation or the end of the study period. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers18
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05535322
GET https://conductscience.org/api/trials/v1/NCT05535322/registered